BLA 125476 · Takeda Pharms USA
Entyvio
Vedolizumab · Injection · Integrin Receptor Antagonist
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
May 20, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
126
35 Phase 3, 30 recruiting
FAERS reports
86,807
75,210 serious, 4,311 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 29, 2026.
ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )
Mechanism: Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with vascular cell adhesion molecule-1 (VCAM-1). The α4β7 integrin is expressed on the surface of a discrete subset of memory T-lymphocytes...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 25, 2023 Supplement 48 · Efficacy
- May 20, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- ENTYVIO · VEDOLIZUMAB 300MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vedolizumab" as an intervention, any sponsor and status, largest first.
- An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's DiseasePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00790933 · 2,243 participants · Start May 22, 2009 · Primary completion Oct 31, 2017
Drug: Vedolizumab · For: Ulcerative Colitis; Crohn's Disease
Sites: Birmingham, Alabama; San Diego, California; San Francisco, California · 41 sites in all
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's DiseasePivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT00783692 · 1,116 participants · Start Dec 2008 · Primary completion Mar 2012
Drug: vedolizumab · For: Crohn's Disease
Sites: Birmingham, Alabama; Los Angeles, California; Montebello, California · 114 sites in all
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruiting
IsalaAcademic, hospital or other
NCT06031233 · 1,082 participants (planned) · Start Sep 1, 2023 · Primary completion Jul 2028
Drug: Nivolumab; Pembrolizumab and 9 more · For: Oncology; Infusion Reaction
Sites: Zwolle, Netherlands
- The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative ColitisPivotal-lookingCompleted
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT07398586 · 898 participants · Start Jan 1, 2020 · Primary completion Dec 31, 2024
Drug: Vedolizumab · For: Ulcerative Colitis (UC)
Sites: Wenzhou, China
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative ColitisPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT00783718 · 895 participants · Start Jan 2009 · Primary completion Dec 2011
Drug: vedolizumab · For: Ulcerative Colitis
Sites: Birmingham, Alabama; Los Angeles, California; Montebello, California · 105 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03819296 · 800 participants (planned) · Start Feb 21, 2021 · Primary completion Oct 31, 2026
Drug: Infliximab; Prednisone and 1 more · For: Clinical Stage 0 Cutaneous Melanoma AJCC v8; Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage IA Cutaneous Melanoma AJCC v8 and 41 more
Sites: Houston, Texas
- An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative ColitisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02497469 · 771 participants · Start Jun 29, 2015 · Primary completion Sep 26, 2018
Drug: Vedolizumab; Adalimumab placebo and 2 more · For: Colitis, Ulcerative
Sites: Mobile, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 330 sites in all
- Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®Pivotal-lookingStatus unknown
Polpharma Biologics S.A.Industry
NCT05771155 · 750 participants (planned) · Start Jul 24, 2023 · Primary completion Sep 2025
Drug: Intravenous (IV) infusions · For: Ulcerative Colitis
Sites: Tbilisi, Georgia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use22,423
- colitis ulcerative15,710
- crohn^s disease11,434
- drug ineffective10,034
- diarrhoea8,781
- abdominal pain7,505
- fatigue6,395
- haematochezia6,172
- frequent bowel movements5,300
- arthralgia4,810
- malaise4,398
- nausea4,215
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 128 |
| 2015 | 1,680 |
| 2016 | 2,930 |
| 2017 | 3,562 |
| 2018 | 4,739 |
| 2019 | 5,511 |
| 2020 | 7,459 |
| 2021 | 10,537 |
| 2022 | 9,447 |
| 2023 | 11,051 |
| 2024 | 12,187 |
| 2025 | 11,222 |
| 2026 | 6,351 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Entyvio (Vedolizumab)
2024 spending
$129M
Beneficiaries
2,863
14,773 claims
Per beneficiary
$45,145
$8,062.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,057,158 |
| 2021 | $58,917,163 |
| 2022 | $75,974,965 |
| 2023 | $99,999,923 |
| 2024 | $129,249,635 |
Part B: Entyvio (Vedolizumab) · HCPCS J3380
2024 spending
$769M
Beneficiaries
19,661
117,555 claims
Per beneficiary
$39,134
2024 ASP limit $22.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $434,494,107 |
| 2021 | $526,528,197 |
| 2022 | $673,755,475 |
| 2023 | $727,761,505 |
| 2024 | $769,418,664 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Schreiber S, Aden K, Bernardes JP, et al. · Gastroenterology 2021 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
- Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Multicenter Study
- Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Kucharzik T, Koletzko S, Kannengiesser K, et al. · Dtsch Arztebl Int 2020 · Meta-Analysis, Review
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E, Wallrabenstein T, König D, et al. · J Immunother Cancer 2024 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.